{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:06:08Z","timestamp":1793649968062,"version":"4.5.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejps.2021.105887","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T12:17:53Z","timestamp":1621426673000},"page":"105887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Gamma sterilization and in vivo evaluation of cationic nanostructured lipid carriers as potential ocular delivery systems for antiglaucoma drugs"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8714-3087","authenticated-orcid":false,"given":"John","family":"Youshia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany O.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhameed","family":"El Shamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105887_bib0001","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3109\/03639045.2010.502534","article-title":"Standardized in vitro drug release test for colloidal drug carriers using modified USP dissolution apparatus I","volume":"37","author":"Abdel-Mottaleb","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0002","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.colsurfa.2007.07.035","article-title":"Effect of beeswax modification on the lipid matrix and solid lipid nanoparticle crystallinity","volume":"315","author":"Attama","year":"2008","journal-title":"Colloids Surf. A Physicochem. Eng. Asp"},{"key":"10.1016\/j.ejps.2021.105887_bib0003","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijpharm.2007.12.007","article-title":"Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct","volume":"355","author":"Attama","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0004","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejpb.2006.12.004","article-title":"Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: Characterization","volume":"67","author":"Attama","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0005","series-title":"Theory and practice of histological techniques","author":"Bancroft","year":"1996"},{"key":"10.1016\/j.ejps.2021.105887_bib0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/08982104.2013.788025","article-title":"Design and optimization of surfactant-based nanovesicles for ocular delivery of Clotrimazole","volume":"23","author":"Basha","year":"2013","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejps.2021.105887_bib0007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0378-5173(96)04822-3","article-title":"Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles","volume":"148","author":"Cavalli","year":"1997","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0008","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1248\/yakushi.130.419","article-title":"Methazolamide calcium phosphate nanoparticles in an ocular delivery system","volume":"130","author":"Chen","year":"2010","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.ejps.2021.105887_bib0009","first-page":"3761","article-title":"Preparation and evaluation of mucoadhesive gellan gum in-situ gels for the ocular delivery of carbonic anhydrase inhibitor nanovesicles","volume":"6","author":"Elazreg","year":"2015","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"10.1016\/j.ejps.2021.105887_bib0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10915818809023137","article-title":"5 Final report on the safety assessment of cetearyl alcohol, cetyl alcohol, isostearyl alcohol, myristyl alcohol, and behenyl alcohol","volume":"7","author":"Elder","year":"1988","journal-title":"J. Am. Coll. Toxicol."},{"key":"10.1016\/j.ejps.2021.105887_bib0011","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ijpharm.2019.06.011","article-title":"Exploring optimized methoxy poly(ethylene glycol)-block-poly(\u03b5-caprolactone) crystalline cored micelles in anti-glaucoma pharmacotherapy","volume":"566","author":"Elmowafy","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0012","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijpharm.2015.10.043","article-title":"Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers","volume":"496","author":"El-Salamouni","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0013","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/archopht.1977.04450080088009","article-title":"Carbonic anhydrase inhibitor side effects: serum chemical analysis","volume":"95","author":"Epstein","year":"1977","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejps.2021.105887_bib0014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0939-6411(98)00074-5","article-title":"Correlation between long-term stability of solid lipid nanoparticles (SLNTM) and crystallinity of the lipid phase","volume":"47","author":"Freitas","year":"1999","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0168-3659(96)01506-4","article-title":"Formulation and testing of methazolamide cyclodextrin eye drop solutions","volume":"44","author":"Fridriksd\u00f3ttir","year":"1997","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2021.105887_bib0016","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejps.2017.11.023","article-title":"Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review","volume":"112","author":"Garc\u00eas","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105887_bib0017","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijpharm.2008.07.028","article-title":"Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity","volume":"364","author":"Gokce","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0018","first-page":"3552","article-title":"Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension","volume":"41","author":"Gu\u0111mundsd\u00f3ttir","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2021.105887_bib0019","doi-asserted-by":"crossref","first-page":"21909","DOI":"10.1021\/acsomega.9b02895","article-title":"Particulate systems in the enhancement of the antiglaucomatous drug pharmacodynamics: a meta-analysis study","volume":"4","author":"Hathout","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejps.2021.105887_bib0020","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1208\/pt0801001","article-title":"Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies","volume":"8","author":"Hathout","year":"2007","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejps.2021.105887_bib0021","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0142-9612(02)00578-1","article-title":"The production and characteristics of solid lipid nanoparticles (SLNs)","volume":"24","author":"Hou","year":"2003","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejps.2021.105887_bib0022","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijpharm.2006.01.040","article-title":"Preparation and characteristics of monostearin nanostructured lipid carriers","volume":"314","author":"Hu","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0023","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-5173(00)00378-1","article-title":"Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids","volume":"199","author":"Jenning","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0024","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.addr.2008.09.002","article-title":"Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery","volume":"60","author":"Jiao","year":"2008","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ejps.2021.105887_bib0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejpb.2008.09.003","article-title":"Lipid nanoparticles for parenteral delivery of actives","volume":"71","author":"Joshi","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2003.09.016","article-title":"Vesicular systems in ocular drug delivery: an overview","volume":"269","author":"Kaur","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0027","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.nano.2010.06.003","article-title":"Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax","volume":"6","author":"Kheradmandnia","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejps.2021.105887_bib0028","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/02652048.2010.539304","article-title":"A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide","volume":"28","author":"Li","year":"2011","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejps.2021.105887_bib0029","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2008.07.017","article-title":"A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers","volume":"363","author":"Li","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejps.2011.09.017","article-title":"Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis","volume":"45","author":"Lopes","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105887_bib0031","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ejps.2021.105887_bib0032","first-page":"64","article-title":"Mathematical comparison of dissolution profiles","volume":"20","author":"Moore","year":"1996","journal-title":"Pharm. Tech."},{"key":"10.1016\/j.ejps.2021.105887_bib0033","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejpb.2004.03.028","article-title":"Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration","volume":"58","author":"M\u00fcller-Goymann","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0034","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1208\/s12249-007-9028-2","article-title":"Lipospheres as carriers for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation","volume":"9","author":"Nasr","year":"2008","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejps.2021.105887_bib0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.colsurfb.2010.07.020","article-title":"Curcuminoids-loaded lipid nanoparticles: Novel approach towards malaria treatment","volume":"81","author":"Nayak","year":"2010","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejps.2021.105887_bib0036","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijpharm.2011.07.040","article-title":"Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application","volume":"419","author":"Pardeike","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0037","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10837450.2020.1731532","article-title":"Voriconazole-loaded self-nanoemulsifying drug delivery system (SNEDDS) to improve transcorneal permeability","volume":"25","author":"Rasoanirina","year":"2020","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2021.105887_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111305","article-title":"Solid lipid nanoparticles for enhanced oral absorption: a review","volume":"196","author":"Salah","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejps.2021.105887_bib0039","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejpb.2016.10.013","article-title":"Lipid nanoparticles (SLN, NLC): overcoming the anatomical and physiological barriers of the eye \u2013 Part II - Ocular drug-loaded lipid nanoparticles","volume":"110","author":"S\u00e1nchez-L\u00f3pez","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0168-3659(94)90047-7","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization","volume":"30","author":"Schwarz","year":"1994","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2021.105887_bib0041","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijpharm.2011.05.044","article-title":"Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake","volume":"415","author":"Tiwari","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105887_bib0042","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jconrel.2004.01.005","article-title":"Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles","volume":"95","author":"Venkateswarlu","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2021.105887_bib0043","doi-asserted-by":"crossref","DOI":"10.2174\/1381612826666200614175236","article-title":"Nanostructured lipid carriers as potential drug delivery systems for skin disorders","author":"Waghule","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejps.2021.105887_bib0044","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/08982104.2014.891231","article-title":"Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box\u2013Behnken design","volume":"24","author":"Wang","year":"2014","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejps.2021.105887_bib0045","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/1061186X.2014.939983","article-title":"Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study","volume":"22","author":"Wang","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2021.105887_bib0046","doi-asserted-by":"crossref","first-page":"411","DOI":"10.7555\/JBR.32.20160170","article-title":"Preparation, optimization, and characterization of chitosan-coated solid lipid nanoparticles for ocular drug delivery","volume":"32","author":"Wang","year":"2018","journal-title":"J. Biomed. Res."},{"key":"10.1016\/j.ejps.2021.105887_bib0047","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0168-3659(97)00046-1","article-title":"Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential","volume":"48","author":"Westesen","year":"1997","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2021.105887_bib0048","first-page":"2483","article-title":"Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide","volume":"7","author":"Youshia","year":"2012","journal-title":"Int. J. Nanomed."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721001883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721001883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:59:51Z","timestamp":1760529591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721001883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":48,"alternative-id":["S0928098721001883"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105887","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gamma sterilization and in vivo evaluation of cationic nanostructured lipid carriers as potential ocular delivery systems for antiglaucoma drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105887"}}